- ►annals.org [PDF] SC Palmer, DO McGregor, P Macaskill, JC … - Annals of Internal Medicine, 2007 - Am Coll Physicians For author affiliations, see end of text. ... A ll stages of chronic kidney
disease (CKD) are associ- ated with significantly increased rates of all-cause
and cardiovascular mortality (1). Several risk factors for death have been ... Cited by 64 - Related articles - BL Direct - All 6 versions
M Tonelli - Annals of internal medicine, 2007 - ncbi.nlm.nih.gov 1: Ann Intern Med. 2007 Dec 18;147(12):880-1. Comment in: Nephrol Dial Transplant.
2008 Aug;23(8):2709-10. Comment on: Ann Intern Med. ... Cited by 13 - Related articles - BL Direct
S Mazzaferro, M Cozzolino, M Marangella, … - G Ital Nefrol, 2007 - sin-italy.org Page 1. S107 Giornale Italiano di Nefrologia / Anno 24 S-37, 2007 / pp.
S107-S124 Terapia della patologia ossea nelle nefropatie croniche ... Cited by 2 - Related articles - View as HTML
F Tentori, JM Albert, EW Young, MJ Blayney, … - Nephrology Dialysis Transplantation, 2008 - ERA-EDTA Background. Retrospective studies of haemodialysis patients from large dialysis
organizations in the United States have indicated that intravenous vitamin D may
be associated with a survival benefit. However, patients prescribed vitamin ... Cited by 12 - Related articles - All 4 versions
M Wolf, A Shah, O Gutierrez, E Ankers, M … - Kidney International, 2007 - nature.com Vitamin D deficiency is associated with cardiovascular disease, the most common
cause of mortality in hemodialysis patients. To investigate the relation between
blood levels of 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D ... Cited by 144 - Related articles - BL Direct - All 8 versions
F Tentori, WC Hunt, CA Stidley, MR … - Kidney international, 2006 - members.medscape.com Intravenous vitamin D is standard therapy for secondary hyperparathyroidism in
hemodialysis (HD) patients. In for-profit dialysis clinics, mortality was higher
for patients on calcitriol compared to paricalcitol. Doxercalciferol, a ... Cited by 132 - Related articles - BL Direct - All 10 versions
GFM Strippoli, S Palmer, A Tong, G Elder, P … - American Journal of Kidney Diseases, 2006 - Elsevier Background: Many randomized trials have now evaluated the effects of
calcimimetics in patients with chronic kidney disease and secondary
hyperparathyroidism (SHPT) on standard therapy with vitamin D and/or ... Cited by 30 - Related articles - All 3 versions
- ►asnjournals.org S Mathew, RJ Lund, LR Chaudhary, T Geurs, … - Journal of the American Society of Nephrology, 2008 - Am Soc Nephrol An apparent conflict exists between observational studies that suggest that
vitamin D receptor (VDR) activators provide a survival advantage for patients
with ESRD and other studies that suggest that they cause vascular ... Cited by 31 - Related articles - All 5 versions
- ►asnjournals.org AB Shoben, KD Rudser, IH de Boer, B Young … - Journal of the American Society of Nephrology, 2008 - Am Soc Nephrol Parenteral vitamin D is associated with improved survival among long-term
hemodialysis patients. Among nondialyzed patients with chronic kidney disease
(CKD), oral activated vitamin D reduces parathyroid hormone levels, but the ... Cited by 37 - Related articles - All 10 versions
K Kalantar-Zadeh, N Kuwae, DL Regidor, CP … - Kidney international, 2006 - medscape.com Although renal osteodystrophy and vitamin D analogs may be related to survival
in maintenance hemodialysis (MHD) patients, most studies have examined
associations between baseline values and survival without accounting for ... Cited by 239 - Related articles - BL Direct - All 8 versions
